14-Methyl-LSD, or 14-Me-LSD, is a serotonin 5-HT2A receptor agonist and possible psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is the derivative of LSD with a methyl group at the 14 position.
The drug is a highly potent full agonist of the serotonin 5-HT2A receptor, with an of 0.5432nM and an of 100.5% in an IP-1 assay. Conversely, it is a very weak partial agonist or antagonist of the serotonin 5-HT2B receptor, with an of 2.319nM and an of 9.838% in an IP-1 assay.
The chemical synthesis of 14-methyl-LSD has been described. The drug's 2-bromo derivative, 2-Br-14-Me-LSD, has also been described. It is a potent serotonin 5-HT2A receptor agonist similarly to 14-methyl-LSD, but with reduced potency and efficacy in comparison. According to the compounds' developers, 14-methyl-LSD may produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, whereas 2-Br-14-Me-LSD may not produce the head-twitch response.
14-Methyl-LSD was described by David E. Nichols and colleagues in association with 2A Biosciences as a key compound in a patent in 2025.
See also Substituted lysergamide 14-Methoxy-LSD 14-Hydroxy-LSD 7-Methylpsilocin (BMB-A39a) 7-Methyl-DMT 7-Me-5-MeO-DMT
References